Trial
NCT04030559
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of California, Davis
Collaborators
National Cancer Institute (NCI); Janssen, LP
Condition
ATM Gene Mutation
Intervention
Niraparib
Why stopped
PI choice; poor accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-14